Neutropenia and Drug-Induced Agranulocytosis

Neutropenia is an absolute neutrophil count (ANC) under about 1.5 ×10⁹/L in adults; severity is graded mild, moderate, or severe, with agranulocytosis — ANC under 0.5 ×10⁹/L — carrying substantially higher infection risk, since neutrophils are the primary early defense against bacterial and fungal pathogens. Causes span chemotherapy-induced neutropenia (covered in the Infections in the Cancer Patient chapter, along with its febrile-neutropenia management and G-CSF prophylaxis), idiosyncratic drug-induced neutropenia/agranulocytosis from non-chemotherapy drugs — the focus of this chapter — autoimmune neutropenia, viral-associated transient neutropenia, and congenital/cyclic neutropenia syndromes. Idiosyncratic drug-induced agranulocytosis is rare but carries real mortality risk from sepsis if unrecognized, and pharmacists are frequently the first to catch it — through a mandatory monitoring program (clozapine) or by recognizing an early infective symptom in a patient recently started on a high-risk drug.^[1]

Neutropenia itself is often asymptomatic until infection develops — the presenting symptoms are usually those of infection (fever, mouth ulcers, sore throat, skin infection) rather than the low count itself, and a neutropenic patient cannot mount a normal inflammatory response, so exam findings (pus, a well-defined infiltrate) are often less impressive than the degree of infection actually present. Idiosyncratic drug-induced agranulocytosis typically has an abrupt onset, often within days to a few months of starting the causative drug — immune-mediated reactions can recur extremely fast (sometimes within hours) on re-exposure, while direct, dose-dependent marrow toxicity tends to develop more gradually.^[1]

Distinguishing the common causes of unexpected neutropenia

• Exposure to a drug with recognized agranulocytosis risk — clozapine, antithyroid drugs (methimazole, propylthiouracil, carbimazole), sulfasalazine, ticlopidine, certain antibiotics (beta-lactams, trimethoprim-sulfamethoxazole), and some antiepileptics (carbamazepine).
• Older age (over 65).
• A higher starting dose or rapid dose escalation of a causative drug (for example, methimazole 30 mg versus 15 mg daily).
• Renal or hepatic impairment, reducing clearance of the causative drug.
• Concurrent bone-marrow-suppressing therapy.
• Underlying autoimmune disease, which increases the risk of immune-mediated neutropenia more broadly.
• Nutritional deficiency (vitamin B12, folate, copper) impairing neutrophil production.
• Recent viral infection — a common, usually self-limited, cause of transient neutropenia, particularly in children.
• Congenital or cyclic neutropenia syndromes (family history).

History

• Full medication history, including the start date of every new drug or dose change in the preceding weeks to months.
• Prior episodes, infection symptoms, autoimmune/rheumatologic history, recent viral illness, and family history.

Examination

Look specifically for signs of infection (oropharynx, skin, perianal region), and for lymphadenopathy or splenomegaly (which suggest an alternate cause) and signs of other cytopenias.

Laboratory evaluation

• CBC with differential and a peripheral smear — confirms the ANC and evaluates the other cell lines and morphology.
• When drug-induced agranulocytosis is suspected, the temporal relationship to the drug start is the key diagnostic clue — no specific confirmatory laboratory test exists. The diagnosis is clinical and temporal, supported by recovery after stopping the drug.^[1]
• Blood cultures (peripheral and any line) before starting antibiotics if febrile.
• Bone marrow examination is not routinely needed for straightforward drug-induced agranulocytosis with a clear temporal relationship and expected recovery — reserve it for an atypical presentation, involvement of other cell lines, failure to recover after stopping the drug, or suspected malignancy/marrow failure.
• Rule out a lab-handling artifact if an isolated, unexpected finding lacks clinical correlation (uncommon, but less common than pseudothrombocytopenia is for platelets).

• Rapidly identify and stop the causative drug when the cause is drug-induced.
• Prevent, detect, and treat infection promptly.
• Support neutrophil recovery with G-CSF when clinically indicated.
• Avoid re-exposure to the causative drug, or a cross-reactive agent in the same class.
• Restore a normal ANC and avoid long-term sequelae.

• Neutropenic precautions during severe neutropenia: emphasize hand hygiene, avoid crowds and sick contacts, and use routine food-safety hygiene (avoid undercooked meat, unwashed produce, and unpasteurized products).
• Avoid elective invasive procedures (dental work, minor surgery) during severe neutropenia where they can reasonably be deferred.
• Maintain good oral hygiene with a soft toothbrush to reduce the risk of mucosal breach.
• Give clear instructions on prompt reporting of fever or infection symptoms, and when to present for urgent care.
• Do not rechallenge with the causative drug — permanent discontinuation is standard for immune-mediated agranulocytosis given the risk of a much faster, more severe recurrence on re-exposure.

Pregnancy

Mild physiologic neutropenia can occur in pregnancy. When neutropenia is drug-induced (for example, from an antithyroid drug used for Graves' disease), stopping or switching therapy requires balancing maternal thyroid control against agranulocytosis risk — this is a specialist-directed decision; propylthiouracil is generally preferred over methimazole specifically in the first trimester for teratogenicity reasons, not because of a materially different agranulocytosis risk between the two.^[3] Filgrastim has been used in pregnancy for severe neutropenia when clearly clinically needed, with reassuring though limited data; it is not used electively.

Breastfeeding

Filgrastim is a large protein molecule with limited breastfeeding data; it is generally considered compatible with breastfeeding when clinically needed given expected minimal oral bioavailability to the infant. Antithyroid drugs (propylthiouracil and methimazole) are compatible with breastfeeding at usual doses.

Pediatrics

Benign, transient post-viral neutropenia is common in children and usually self-limited, needing no treatment. Drug-induced agranulocytosis is less common in children but can occur (for example, with antiepileptics). Autoimmune neutropenia of infancy is a distinct, usually benign, self-limited entity.

Clozapine-specific monitoring

Patients on clozapine require lifelong scheduled hematologic monitoring under the mandatory Canadian monitoring program. Follow the program's specific ANC action thresholds exactly for continuing, interrupting, or permanently discontinuing therapy — this is not a situation for ad hoc clinical judgment in place of the defined program rules, and monitoring frequency is highest in the first several months of treatment, when risk is greatest.

Renal/hepatic impairment

Dose-adjust the causative drug appropriately per its own monograph. Filgrastim does not require specific renal or hepatic dose adjustment, but use general caution in a critically unwell patient.

Serial CBC with differential — daily during acute severe agranulocytosis or hospitalization, then per the recovery trend. Expect neutrophil recovery within 1-3 weeks after stopping the causative drug in most idiosyncratic cases; if recovery has not begun by then, reassess the diagnosis (consider marrow failure or an alternate cause) and consider bone marrow examination. Give clear temperature-monitoring and when-to-seek-care instructions for outpatient-managed mild-to-moderate cases. For high-risk maintenance drugs (clozapine, antithyroid drugs, sulfasalazine), follow the drug-specific mandatory or scheduled CBC monitoring protocol, especially during the first several months of therapy. Document the causative drug clearly in the patient's allergy/intolerance record and counsel that re-exposure is generally contraindicated for life.

1. Confirm the presumed causative drug has genuinely been stopped, and that no cross-reactive agent (for example, another thioamide antithyroid drug) has been substituted in its place.
2. If the ANC has not begun recovering within 1-3 weeks of stopping the drug, reassess the diagnosis — consider bone marrow examination to exclude an alternate cause (marrow failure, malignancy, myelodysplasia).
3. Add filgrastim if not already started and recovery is delayed or the patient remains at high infection risk.
4. For persistent antibody-mediated agranulocytosis despite drug cessation and G-CSF, consider IVIG or a short corticosteroid course under specialist direction.
5. If fever or infection develops or persists despite supportive care, escalate empiric antimicrobial therapy per current culture data and local protocol, and involve infectious diseases/hematology.
6. For recurrent, unexplained neutropenia without a clear drug cause, refer for hematology workup of chronic, congenital, or autoimmune neutropenia syndromes.

• Rechallenging a patient with the suspected causative drug "to confirm" the diagnosis — this risks a much faster, more severe recurrence in immune-mediated agranulocytosis and should essentially never be done deliberately.
• Switching to another drug in the same high-cross-reactivity class after antithyroid-drug agranulocytosis (for example, methimazole to propylthiouracil) without specialist input.
• Attributing fever in a neutropenic patient to a benign cause and delaying antibiotics while awaiting confirmatory cultures.
• Ordering a bone marrow examination reflexively for every case of drug-induced agranulocytosis with a clear temporal drug relationship and an expected recovery course.
• Missing a new high-risk drug start, or a recent dose increase, as the cause of new neutropenia found on routine bloodwork.
• Forgetting to document the causative drug and to counsel the patient and prescriber against future re-exposure.
• Assuming G-CSF is required for every case of drug-induced neutropenia rather than reserving it for severe or complicated presentations.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Antibiotic selection for febrile neutropenia and cycle-based G-CSF prophylaxis dosing for chemotherapy are covered in the companion Infections in the Cancer Patient chapter, not reproduced here. Select any drug name to open its complete Pharmasist Drug Database page.

Hematopoietic growth factors (G-CSF)

Reserved for severe drug-induced agranulocytosis with infection or other high-risk features, not routine mild-moderate neutropenia.

Immune-mediated agranulocytosis adjuncts

Reserved for refractory antibody-mediated agranulocytosis despite drug cessation and G-CSF, under specialist direction — limited evidence base.

Drugs commonly implicated in idiosyncratic neutropenia/agranulocytosis

This list is not exhaustive — consider any recently started or dose-increased drug as a possible cause, and check the specific product monograph.

Evidence note: drug inventory, dosing, adverse effects, and comments reflect standard Canadian practice, cross-checked against current primary literature.^[1]